<DOC>
	<DOCNO>NCT01931033</DOCNO>
	<brief_summary>This study 8-week open-label trial test oxytocin nasal spray ( Syntocinon ) treatment social impairment adolescent autism spectrum disorder ( ASD ) . We hypothesize oxytocin nasal spray safe , tolerable , effective improve core symptom autism spectrum disorder adolescent age 11-17 .</brief_summary>
	<brief_title>An Open-Label Trial Oxytocin Adolescents With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female outpatient age 1117 year 2 . DSMIVTR PDD diagnosis autistic disorder , Asperger 's disorder , PDDNOS establish clinical diagnostic interview aid MGH ASD Symptom Checklist ( MGHASDSCL ) . 3 . At least moderate severity ASD impairment measure raw score ≥80 SRS severity score ≥4 CGIPDD . 4 . Participants parent/guardian must able speak understand English sufficiently comprehend nature study allow completion study procedure require per protocol . 5 . Subjects parent/guardian must consider reliable reporter . 6 . Each subject parent/guardian must understand nature study provide write informed assent/consent . 7 . Subjects must able participate mandatory blood draw . 8 . Subjects mood , anxiety , disruptive behavior disorder allow participate study provide meet exclusionary criterion . Exclusion Criteria 1 . IQ &lt; 85 2 . Total lack spoken language 3 . DSMIVTR PDD diagnosis Rett 's disorder childhood disintegrative disorder . 4 . Clinically unstable psychiatric condition judge serious suicidal risk determine evaluate investigator . 5 . History substance use ( except nicotine caffeine ) within past 3 month 6 . Serious , stable unstable systemic illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 7 . Subjects severe hepatic impairment ( LFTs &gt; 3 time ULN ) severely impaired renal function ( eGFR &lt; 30 ) . 8 . Pregnant nursing female . 9 . Known hypersensitivity oxytocin . 10 . Severe allergy multiple adverse drug reaction . 11 . A nonresponder history intolerance oxytocin , treatment adequate dos determine clinician . 12 . Subjects significant nasal pathology ( include atrophic rhinitis , recurrent nose bleeds , history hypophysectomy ) . 13 . Investigator his/her immediate family define investigator 's spouse , parent , child , grandparent , grandchild . 14 . Currently enrol recently participate ( within past 6 month ) clinical trial intranasal oxytocin .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
	<keyword>ASD</keyword>
	<keyword>PDD</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Syntocinon</keyword>
	<keyword>treatment</keyword>
</DOC>